Clinical Trials Browser

OTHER × Cetuximab × Clear all

NCT02128906 2026-04-16

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Phase 2 Recruiting

Carcinoma, Squamous Cell, Laryngeal Diseases

NCT05745857 2026-04-13

SLURP

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07441681 2026-04-03

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03370276 2026-04-02

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 1/2 Completed

95 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck, Neoplasms, Squamous Cell

NCT06369259 2026-04-01

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Advanced Colorectal Cancer

NCT04722523 2026-03-30

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05200442 2026-03-30

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07490119 2026-03-24

Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer

Phase 2 Not yet recruiting

RAS Wild Type mCRC

NCT02215720 2026-03-20

TORERO

Phase 1 Completed

Other solid neoplasm

Patients With Advanced or Metastatic Solid Tumors

NCT01647555 2026-03-18

Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Head and Neck Neoplasms

NCT04375384 2026-03-18

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04883281 2026-03-18

DARTBOARD

Phase 2 Completed

Head and Neck Neoplasms

NCT05985954 2026-03-12

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07411599 2026-03-12

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Cancer, Hereditary Nonpolyposis, Type 6, Carcinoma, Colorectal Neoplasms

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Phase EARLY_PHASE1 Active not recruiting

Gastrointestinal

Colonic Neoplasms

NCT03446157 2026-03-10

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Phase 2 Completed

24 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms

NCT06412198 2026-03-06

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05722327 2026-03-04

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

Phase 1 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04290546 2026-02-27

CIML NK Cell in Head & Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT06239220 2026-02-27

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07217028 2026-02-27

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Phase 1 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Phase EARLY_PHASE1 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07432087 2026-02-25

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06855212 2026-02-20

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05041127 2026-02-19

Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma

Phase 2 Active not recruiting

Chordoma

NCT07063212 2026-02-19

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07404527 2026-02-13

Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery

Phase NA Recruiting

Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms

NCT03693807 2026-02-06

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Phase 2 Completed

35 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms, Cholangiocarcinoma

NCT00556413 2026-02-05

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03944941 2026-02-05

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Phase 2 Active not recruiting

Skin Neoplasms

NCT04587128 2026-02-05

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07389265 2026-02-05

CAPRI-3 GOIM

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02979977 2026-02-04

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Phase 2 Completed

50 enrolled 14 charts

Squamous Cell Cancers of the Head and Neck

NCT07381764 2026-02-02

ROMANCE - GOIM

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT05040568 2026-01-26

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colonic Neoplasms

NCT06358430 2026-01-15

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT04229459 2026-01-14

Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.

Phase 2 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07094893 2026-01-14

ARIEL-ENGIC

Phase 4 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT01025089 2026-01-07

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

Phase 2 Active not recruiting

Thymoma

NCT03290937 2026-01-06

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

NCT06332079 2026-01-05

HAITI

Phase 2 Terminated

Gastrointestinal

Colorectal Cancer Metastatic

NCT06578559 2026-01-05

BRICKET

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02270814 2025-12-30

CACTUX

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06998069 2025-12-30

Head and Neck Cancer Study Project in the Geriatric Population

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01827956 2025-12-29

FCR-VADS

121 enrolled 7 charts

Upper Gingival Squamous Cell Carcinoma

NCT04616183 2025-12-23

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06540326 2025-12-22

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

Phase 2 Recruiting

Gastrointestinal

Colorectal Cancer Metastatic